The results of a systematic review of pharmacologic treatments in patients with MG showed that mycophenolate and Ig or plasma exchange drugs have positive effects. Thymectomy may be considered in patients with generalized MG without detectable AChR antibodies if they do not respond adequately to immunosuppressant therapy or to avoid/minimize intolerable adverse effects from immunosuppressant therapy.
Therapeutic plasmapheresis or plasma replacement is the first line of treatment in patients with MG who have respiratory failure, the inability to swallow, myasthenic crisis, or an inadequate response to drug therapy. Intermittent intravenous methylprednisolone is used to treat several autoimmune disorders, including severe cases of MG.
Learn more about first-line MG treatments.
This Rapid Review Quiz was excerpted and adapted from the Medscape articles Positive Top-Line Phase 3 Results for Novel Myasthenia Gravis Drug, FDA Approves New Myasthenia Gravis Drug, Efgartigomod, Pyridostigmine, Myasthenia Gravis, and Prednisone.
Follow Medscape on Facebook, Twitter, Instagram, and YouTube
Credits:
Lead image: Jormonago/Dreamstime
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Rapid Rx Quiz: Myasthenia Gravis Treatments - Medscape - Mar 15, 2022.
Comments